mepenzolate 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
1689 25990-43-6

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • mepenzolate
  • mepenzolon
  • mepenzolate bromide
anticholinergic, antispasmodic agent; RN given refers to parent cpd; structure
  • Molecular weight: 340.44
  • Formula: C21H26NO3
  • CLOGP: 0.16
  • LIPINSKI: 0
  • HAC: 4
  • HDO: 1
  • TPSA: 46.53
  • ALOGS: -5.78
  • ROTB: 5
  • Status: OFM
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
0.10 g O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Bocci G, Oprea TI, Benet LZ

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
azlogd74 LogD at pH 7.4 -0.499 High 1
caco2-efflux Caco-2 efflux ratio (BA/AB) 2.366 High 1
caco2-intrinsic-papp Caco-2 intrinsic apparent permeability 0.652 10^-6 cm/s High 1
dh-clint Dog hepatocyte intrinsic clearance 4.519 uL/min/10^6 cells High 1
dppb Dog plasma protein binding (% unbound) 69.030 % High 1
fcs-ppb Fetal calf serum protein binding (% unbound) 61.910 % High 1
herg hERG pIC50 4.525 pIC50 High 1
hh-clint Human hepatocyte intrinsic clearance 1.396 uL/min/10^6 cells High 1
hlm-clint Human liver microsomal intrinsic clearance 3.981 uL/min/mg protein High 1
hppb Human plasma protein binding (% unbound) 63.470 % High 1
kinase-safety-class ACVR2A,ACVR2B,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK5,CDK9,DYRK1B,EIF2AK3,EPHB4,ERBB2,GRK2,ITK,MAP3K7,MAPK7,NTRK2,PDK1,PDK2,PDK4,PIK3CB,PRKDC,SIK2,SIK3,TEK,TGFBR1 27
kinase-selectivity-class AXL,GRK2,PDK4 3
mdck-mdr1-efflux MDCK-MDR1 efflux ratio 1.500 High 1
mh-clint Mouse hepatocyte intrinsic clearance 75.683 High 1
mppb Mouse plasma protein binding (% unbound) 67.580 High 1
nih-mdck-mdr1-efflux NIH MDCK-MDR1 efflux ratio 2.249 High 1
pfas-class PFAS structural alert (1 = True, 0 = False) 0
pppb Pig plasma protein binding (% unbound) 76.810 % High 1
rh-clint Rat hepatocyte intrinsic clearance 117.220 uL/min/10^6 cells High 1
rh-fuinc Rat hepatocyte fraction unbound in incubation 84.780 % High 1
rppb Rat plasma protein binding (% unbound) 58.610 % High 1
solubility-dd Solubility at pH 7.4 in DMSO 901.571 uM High 1

Approvals:

DateAgencyCompanyOrphan
Nov. 14, 1956 FDA SANOFI AVENTIS US

FDA Adverse Event Reporting System (Female)

None

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

None

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC A03AB12 ALIMENTARY TRACT AND METABOLISM
DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS
DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS
Synthetic anticholinergics, quaternary ammonium compounds
FDA MoA N0000175370 Cholinergic Antagonists
FDA EPC N0000175574 Anticholinergic

Related Drugs by ATC class:

A03AB Synthetic anticholinergics, quaternary ammonium compounds 19 drugs
(2-benzhydryloxyethyl)diethyl-methylammonium iodidebenziloniumbevoniumdiphemanilfenpiveriniumglycopyrronium bromidehexocycliumisopropamidemethantheliniumotilonium bromideoxyphenoniumpenthienate show all 19 →

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Peptic ulcer indication 13200003 DOID:750
Gastric ulcer indication 397825006 DOID:10808
Irritable bowel syndrome off-label use 10743008 DOID:9778
Tachyarrhythmia contraindication 6285003
Urinary tract obstruction contraindication 7163005 DOID:5200
Disorder of autonomic nervous system contraindication 15241006
Glaucoma contraindication 23986001 DOID:1686
Toxic megacolon contraindication 28536002 DOID:1770
Atony of colon contraindication 29479008
Hyperthyroidism contraindication 34486009 DOID:7998
Hypertensive disorder contraindication 38341003 DOID:10763
Conduction disorder of the heart contraindication 44808001
Chronic heart failure contraindication 48447003
Paralytic ileus contraindication 55525008 DOID:8442
Peptic reflux disease contraindication 57643001
Ulcerative colitis contraindication 64766004 DOID:8577
Kidney disease contraindication 90708001 DOID:557
Myasthenia gravis contraindication 91637004 DOID:437
Gastrointestinal obstruction contraindication 126765001
Bleeding contraindication 131148009
Disease of liver contraindication 235856003 DOID:409
Benign prostatic hyperplasia contraindication 266569009
Disorder of coronary artery contraindication 414024009




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 13.68 acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Muscarinic acetylcholine receptor M1 GPCR ANTAGONIST CHEMBL CHEMBL
Muscarinic acetylcholine receptor M3 GPCR ANTAGONIST Ki 8.59 CHEMBL CHEMBL
Muscarinic acetylcholine receptor M2 GPCR Ki 9.17 CHEMBL
Solute carrier family 22 member 1 Transporter IC50 4.19 CHEMBL

External reference:

IDSource
4019812 VUID
N0000147901 NUI
D00720 KEGG_DRUG
76-90-4 SECONDARY_CAS_RN
4018609 VANDF
4019812 VANDF
C0360172 UMLSCUI
CHEBI:6752 CHEBI
CHEMBL524004 ChEMBL_ID
DB04843 DRUGBANK_ID
CHEMBL1724 ChEMBL_ID
C005101 MESH_SUPPLEMENTAL_RECORD_UI
4057 PUBCHEM_CID
ONW3LB39P7 UNII
107770 RXNORM
5045 MMSL
d00995 MMSL
001746 NDDF
004701 NDDF
372834001 SNOMEDCT_US
60289002 SNOMEDCT_US
74022005 SNOMEDCT_US
889 INN_ID
ONW3LB39P7 INXIGHT DRUGS

Pharmaceutical products:

None